Miransertib
7075-002
Phase 2 small_molecule terminated
Quick answer
Miransertib for PIK3CA-Related Overgrowth Spectrum (PROS)/Proteus Syndrome is a Phase 2 program (small_molecule) at Merck KGaA, Darmstadt, Germany with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Merck KGaA, Darmstadt, Germany
- Indication
- PIK3CA-Related Overgrowth Spectrum (PROS)/Proteus Syndrome
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- terminated